💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Trilaciclib Dihydrochloride

CHEMBL4650272 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
519.5 g/mol
LogP
—
Phase
4

Trilaciclib dihydrochloride is the dihydrochloride salt form of trilaciclib, a CDK4/6 inhibitor that transiently induces G1 cell cycle arrest in hematopoietic progenitor cells to protect bone marrow during chemotherapy. It reduces the need for granulocyte colony-stimulating factor and red blood cell transfusions following myelosuppressive chemotherapy. This salt form is used in the clinical formulation of the intravenous product.

الوزن الجزيئي

519,5000 g/mol

TPSA

91,20 Ų

المجالات العلاجية

Bladder Cancer Breast Cancer

آلية العمل

Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1.Cl.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C24H30N8O.2ClH/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23;;/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29);2*1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H32Cl2N8O

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
الروابط القابلة للدوران

                        
3

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Trilaciclib dihydrochloride is the dihydrochloride salt form of trilaciclib, a CDK4/6 inhibitor that transiently induces G1 cell cycle arrest in hematopoietic progenitor cells to protect bone marrow during chemotherapy. It reduces the need for granulocyte colony-stimulating factor and red blood cell transfusions following myelosuppressive chemotherapy. This salt form is used in the clinical formulation of the intravenous product.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Trilaciclib Dihydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4650272.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 124081865.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.